
In the midst of a greater stock fluctuation for US-based IGM Biosciences, the company has entered a multimillion-dollar deal with French Sanofi, a competitor of Novo Nordisk on the insulin area. In aggregate numbers, the deal could reach over USD 6bn, a joint press release reports.
A more modest USD 150m starts the partnership off, with IGM Biosciences being the recipient of the upfront payment while Sanofi further expresses an interest in purchasing IGM shares for up to USD 100m.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app